AQXP:NSD-Neoleukin Therapeutics, Inc (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 4.03

Change

0.00 (0.00)%

Market Cap

USD 0.10B

Volume

0.27M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

AQXP Stock Forecast & Price:
Based on the Neoleukin Therapeutics, Inc stock forecasts from 0 analysts, the average analyst target price for Neoleukin Therapeutics, Inc is not available over the next 12 months. Neoleukin Therapeutics, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Neoleukin Therapeutics, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Neoleukin Therapeutics, Inc’s stock price was USD 4.03. Neoleukin Therapeutics, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Neoleukin Therapeutics, Inc
No recent average analyst rating found for Neoleukin Therapeutics, Inc

About Neoleukin Therapeutics, Inc (AQXP:NSD)

Aquinox Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering and developing therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aq ...Read More

Company Website : http://www.aqxpharma.com

Address : 887 Great Northern Way, Suite 450 V5T 4T5,Vancouver,CAN

Employees : 8

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.92

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

 USD61,525,874.67B 1.10 5.30
FTD FTD Companies, Inc

N/A

 USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

 USD24,651,104.38B 166.80 24.48
SNHY Helios Technologies, Inc

N/A

 USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

 USD8,997,243.52B 175.07 79.98
INSY INSYS Therapeutics, Inc

N/A

 USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

 USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

 USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

 USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

 USD38,513.36B N/A N/A

ETFs Containing AQXP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -71.60% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.60% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.06% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.06% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.81% N/A N/A N/A N/A
Risk Adjusted Return -2.31% N/A N/A N/A N/A
Market Capitalization 0.10B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -3.28 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -26.25% N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.92 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.